By the year 2050, the world will need to increase food production by some 70 per cent to feed an estimated global population of 9.1billion. With the wider population discovering the disadvantages and unsustainability of the production of red meat and as natural resource constraints intensify, the demand for efficiently produced proteins such as aquaculture and poultry will increase.
Imugenics' technology provides a multi-pronged approach to provide an efficient and low-cost method of disease control, without the use of vaccines and antibiotics.
Leveraging a combination of technology and biology developed by a consortium of global scientific research leaders, Imugenics' approach utilizes proprietary and patent-pending naturally occurring bacteria designed to protect animals against diseases and pests. This will give growers the ability to farm animals without the use of antibiotics, and provide a cheap alternative to antigen protection.
Direct healthcare costs due to antibiotic over-use ranged as high as $20 billion in the U.S., and a loss of productivity is estimated to reach $35 billion in the next decade (2014).
Antibiotic over-use contributes to the spread of drug-resistant pathogens in both livestock and humans, posing a significant public health threat.
Novel solutions are needed to tackle the increasing demand for efficient animal proteins and the widespread disease outbreaks caused by high density containment systems.
Imugenics' initial focus is on the shrimp and aquaculture industry.
The aquaculture sector has the lowest medicalization rates among any livestock category, with diseases such as White Spot Syndrome Virus (WSSV) resulting in up to 100% mortality rates within a few days of outbreak. Vaccines are not effective in shrimp, and in the U.S. alone shrimp accounts for 26 to 35% of imported seafood that is rejected due to contamination.
Disease outbreaks in world fish and shellfish production result in $6 billion lost annually across the globe (2015).
Imugenics' innovation consists of naturally-occurring bacteria expressing small interfering RNAs that inactive the expression of target genes. Our solution uses novel integrated delivery mechanisms to combat animal health problems. Specifically, it:
- Provides robust antigen protection, resulting in improved disease immunity due to self-replicating bacteria;
- Reduces likelihood of resistant mechanisms evolving (multiple-variant approach);
- Incorporates bio-safety mechanisms to prevent modified DNA being released into the wild;
- Can be utilized to disable replication of multiple viruses at one time, and is easily adaptable to be quickly deployed to address emerging viral and fungal disease affecting specific regions;
- Removes expensive cold chain requirement (problematic particularly within emerging countries);
- Provides a long and stable shelf life;
- Is efficient to manufacture and deploy in scale worldwide; and
- Is simple and low cost to handle and disperse.
+ DR. FADIA SAAD, PRESIDENT
- 20 years experience in the biotechnology and pharma space, with expertise in bridging science and business
- Previous executive positions in a number of biotechnology companies including Aspreva Pharmaceuticals, MedBiogene and Green Sky Labs
+ JON BLOODWORTH, CHIEF OPERATING OFFICER
- Three decades of senior executive management and legal experience in disruptive technologies, with an emphasis on intellectual property protection and licensing, commercial negotiations, finance and venture development
- Holds a law degree and is an active member of the State Bar of California
+ DR. RICHARD SAYRE, CHIEF SCIENTIFIC OFFICER
- One of the top Research Scientists at Los Alamos National Laboratory and the New Mexico Consortium
- Extensive biotech experience in universities, national laboratories, and the private sector
- One of the top 5 crop scientists who could change the world, according to Nature journal
- Author of over 130 biotechnology papers and patents, with over 7000 citations
- Received over US$100 million in grant funding for various projects
+ KIMBERLY HARRISON, CHIEF DEVELOPMENT OFFICER
- 25 years experience as an entrepreneur across industries
- Experienced in strategy, product development, VC funding, patents, distribution/licensing, and government relations
- Served on numerous international product certifications and standardization committees
+ DR. KONSTANTINOS LYMPEROPOULOS, SCIENTIST
- PhD in Biochemistry from the University of Oxford with a solid scientific background in biochemistry, virology and biophysics
- Expertise in bio-molecular interactions, novel technology platforms and gene therapy
- Author of 11 publications
+ DR. GUOHUA (KAREN) YIN, SCIENTIST
- PhD in Molecular Plant Pathology from the State Key Laboratory of Crop Biology in Shandong China
- Skilled in molecular biology and biotechnology such as next-generation sequencing and re-sequencing
- Author of 45 publications with another 11 under review or in preparation
+ DR. TATIANA VINOGRADOVA-SHAH, SCIENTIST
- PhD in Cell Biology from the Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia
- Expertise in cell and developmental biology
- Author of 11 publications
+ DR. PEDRO MIGUEL MELO DA COSTA NUNES, SCIENTIST
- PhD in Biology from the Instituto Superior de Agronomia, Technical University of Lisbon, Lisbon, Portugal
- Expertise in plant Argonaute diversity and function
- Author of 22 publications
+ SHANNON FLYNN, TECHNICIAN
- 20 years experience in the Department of Energy's environmental science and restoration departments
Board of Directors
+ MICHAEL HARRISON, CHIEF EXECUTIVE OFFICER & CHAIRMAN OF THE BOARD
- 35 years experience in investment banking with interests in the resource, energy and biotech sectors
- Responsible for raising in excess of US$1 billion in funding for private and publicy traded companies
- Served on the Board of Directors for numerous international publicly listed companies
+ EDWARD CHEUNG, DIRECTOR
- Over 20 years experience at global investment banks including JPMorgan, Lehman Brothers and Credit Suisse, advising on equities and derivatives to institutions, hedge funds and sovereign wealth funds
- Experience in setting up new businesses including a trading division at a US bank and board member of several startups
+ DAVID SMALLEY, CHIEF COUNSEL
- 17 years practising corporate and securities law, providing legal services for financing private and public companies
- Director of a number of Capital Pool Companies listed for trading on the TSX-Venture Exchange in Canada
- Advises CEOs on their financing and business strategies; provides corporate, commercial and securities legal services
Imugenics is collaborating with world-class research institutions to ensure our science is successful.
New Mexico Consortium (NMC)
Imugenics operates within the award winning facilities of the NMC. Our Chief Scientific Officer, Dr. Richard Sayre, a Senior Research Scientist at the Los Alamos National Laboratory, leads our team of dedicated research scientists.
Harbor Branch Oceanographic Institute at Florida Atlantic University (HBOI)
HBOI is a research institute focusing on biological oceanography, aquaculture and the development of natural products for medicines and other uses within the aquatic world. HBOI will work with us to help with testing and virology within the aquaculture space.
National Center for Genome Resources USA (NCGR)
NCGR is a research institute that applies bioinformatics, software engineering and next-generation sequencing to solve the preeminent challenges of 21st century biology through collaborative research and services.
Dr. Callum Bell, President, has extensive expertise in transforming advances in genome sequencing into clinical practice.
+1 778 928 6973